Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"
Jump to navigation
Jump to search
(Coronary heart disease events: One line break ought to be enough with parenthesis around. Template:Dfn to assist screen readers.) |
(Replace pseudo-footnote with ref-tag footnotes (MOS:NOTES)) |
||
| Line 2: | Line 2: | ||
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative | |+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative | ||
|- | |- | ||
| − | ! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}} | + | ! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8506) |
|- | |- | ||
! colspan="2" | Absolute Risk per 10,000 Women-Years | ! colspan="2" | Absolute Risk per 10,000 Women-Years | ||
| Line 8: | Line 8: | ||
| [[Coronary heart disease]] events<br />({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63)<br />1.32 (1.02–1.72)<br />1.18 (0.70–1.97) || 30<br />23<br />6 || 37<br />30<br />7 | | [[Coronary heart disease]] events<br />({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63)<br />1.32 (1.02–1.72)<br />1.18 (0.70–1.97) || 30<br />23<br />6 || 37<br />30<br />7 | ||
|- | |- | ||
| − | | [[Invasive breast cancer]] | + | | [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38 |
|- | |- | ||
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29 | | [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29 | ||
| Line 22: | Line 22: | ||
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37 | | Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37 | ||
|- | |- | ||
| − | | Global Index | + | | Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170 |
|- | |- | ||
| − | | [[Deep vein thrombosis]] | + | | [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26 |
|- | |- | ||
| − | | [[Vertebral fracture]]s | + | | [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9 |
|- | |- | ||
| − | | Other [[osteoporotic fracture]]s | + | | Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131 |
|- class="sortbottom" | |- class="sortbottom" | ||
| − | | colspan="10" style="width: 1px;" | '''Abbreviations:''' WHI = {{No selflink|Women's Health Initiative}}. CEEs = {{No selflink|Conjugated estrogens}}. MPA = {{No selflink|Medroxyprogesterone acetate}}. '''Notes:''' Dosages were 0.625 mg/day CEEs and 2.5 mg/day MPA | + | | colspan="10" style="width: 1px;" | '''Abbreviations:''' WHI = {{No selflink|Women's Health Initiative}}. CEEs = {{No selflink|Conjugated estrogens}}. MPA = {{No selflink|Medroxyprogesterone acetate}}. '''Notes:''' Dosages were 0.625 mg/day CEEs and 2.5 mg/day MPA. '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref> |
|}<!-- | |}<!-- | ||
--><noinclude> | --><noinclude> | ||
| − | == | + | ==Notes and references== |
{{Reflist}} | {{Reflist}} | ||
| + | {{Notelist}} | ||
| + | {{Notefoot}} | ||
[[Category:Medication templates]] | [[Category:Medication templates]] | ||
[[Category:Templates that generate named references]] | [[Category:Templates that generate named references]] | ||
</noinclude> | </noinclude> | ||
Revision as of 09:27, 27 March 2019
| Event | Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI[note 1]) | Placebo (n = 8102) |
CEEs/MPA (n = 8506) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Absolute Risk per 10,000 Women-Years | |||||||||
| Coronary heart disease events ( non-fatal myocardial infarction, death) |
1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) |
30 23 6 |
37 30 7 | ||||||
| Invasive breast cancer[lower-alpha 1] | 1.26 (1.00–1.59) | 30 | 38 | ||||||
| Stroke | 1.41 (1.07–1.85) | 21 | 29 | ||||||
| Pulmonary embolism | 2.13 (1.39–3.25) | 8 | 16 | ||||||
| Colorectal cancer | 0.63 (0.43–0.92) | 16 | 10 | ||||||
| Endometrial cancer | 0.83 (0.47–1.47) | 6 | 5 | ||||||
| Hip fracture | 0.66 (0.45–0.98) | 15 | 10 | ||||||
| Death due to causes other than above | 0.92 (0.74–1.14) | 40 | 37 | ||||||
| Global Index[lower-alpha 2] | 1.15 (1.03–1.28) | 151 | 170 | ||||||
| Deep vein thrombosis[lower-alpha 3] | 2.07 (1.49–2.87) | 13 | 26 | ||||||
| Vertebral fractures[lower-alpha 3] | 0.66 (0.44–0.98) | 15 | 9 | ||||||
| Other osteoporotic fractures[lower-alpha 3] | 0.77 (0.69–0.86) | 170 | 131 | ||||||
| Abbreviations: WHI = Template:No selflink. CEEs = Template:No selflink. MPA = Template:No selflink. Notes: Dosages were 0.625 mg/day CEEs and 2.5 mg/day MPA. Sources: [1][2] | |||||||||
Notes and references
- ↑ Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
- ↑ Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.
- ↑ Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.
- ↑ A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
- ↑ 3.0 3.1 3.2 Not included in Global Index.
Cite error: <ref> tags exist for a group named "note", but no corresponding <references group="note"/> tag was found, or a closing </ref> is missing